Mack William J, Mocco J, Hoh Daniel J, Huang Judy, Choudhri Tanvir F, Kreiter Kurt T, Lozier Alan, Opperman Marcello, Poisik Alexander, Yorgason Joshua, Solomon Robert A, Mayer Stephan A, Connolly E Sander
Department of Neurology and Neurological Surgery, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA.
J Neurosurg. 2002 Jan;96(1):71-5. doi: 10.3171/jns.2002.96.1.0071.
Although upregulated adhesion molecule expression has been demonstrated in experimental models of subarachnoid hemorrhage (SAH) and in the cerebrospinal fluid of patients with aneurysmal SAH, the clinical significance of these proinflammatory findings remains unclear. The authors hypothesize that 1) serum levels of soluble intercellular adhesion molecule-l (ICAM-1) are increased in all patients with aneurysmal SAH shortly after the hemorrhagic event, and 2) elevated soluble ICAM-1 values are associated with poor patient outcome, even when controlling for the severity of the initial hemorrhagic insult.
One hundred one patients were prospectively enrolled and stratified according to their admission Hunt and Hess grade and functional status at discharge (modified Rankin Scale [mRS] score). Soluble ICAM-1 levels were determined every other day for 12 days post-SAH by using the enzyme-linked immunosorbent assay. Early soluble ICAM-1 levels (post-SAH Days 2-4) were increased compared with levels in control patients without SAH (p < 0.05). Patients with aneurysmal SAH who had a poor outcome (mRS Grades 4-6) had significantly higher soluble ICAM-1 levels over the first 2 weeks post-SAH compared with patients who had a good outcome (mRS Grades 0-3, p < 0.01). This association with outcome was predicted by late increases (Day 6, p = 0.07; Days 8-12, p < 0.05) rather than early increases (p = not significant) and was best seen in patients with Hunt and Hess Grades I and II. in whom only those with poor outcomes demonstrated delayed ICAM-1 elevations (p < 0.05).
These data demonstrate a correlation between soluble ICAM-1 levels and functional outcome following aneurysmal SAH that appears to be, at least in part, independent of the initial hemorrhage.
尽管在蛛网膜下腔出血(SAH)的实验模型以及动脉瘤性SAH患者的脑脊液中已证实粘附分子表达上调,但这些促炎结果的临床意义仍不明确。作者推测:1)所有动脉瘤性SAH患者在出血事件后不久血清可溶性细胞间粘附分子-1(ICAM-1)水平都会升高;2)即使在控制初始出血损伤的严重程度后,可溶性ICAM-1值升高仍与患者预后不良相关。
前瞻性纳入101例患者,并根据其入院时的Hunt和Hess分级以及出院时的功能状态(改良Rankin量表[mRS]评分)进行分层。在SAH后12天内每隔一天使用酶联免疫吸附测定法测定可溶性ICAM-1水平。与无SAH的对照患者相比,SAH后早期(SAH后第2 - 4天)可溶性ICAM-1水平升高(p < 0.05)。与预后良好(mRS分级0 - 3)的患者相比,预后不良(mRS分级4 - 6)的动脉瘤性SAH患者在SAH后的前2周内可溶性ICAM-1水平显著更高(p < 0.01)。这种与预后的关联是由后期升高(第6天,p = 0.07;第8 - 12天,p < 0.05)而非早期升高(p = 无显著性差异)预测的,并且在Hunt和Hess分级为I级和II级的患者中最为明显,其中只有预后不良的患者表现出ICAM-1延迟升高(p < 0.05)。
这些数据表明动脉瘤性SAH后可溶性ICAM-1水平与功能预后之间存在相关性,这似乎至少部分独立于初始出血情况。